您現在位置：健康網-醫藥產業 >> 研究報告 >> English reports >> English reports >> 瀏覽醫藥行業研究報告
Market Report of Monoclonal Antibody Drugs in China (2022)
[關鍵字]： mAb PD-1 ADC BsAb CTLA-4 DS-8201 BeiGene RemeGen Akeso TopAlliance Innovent Henlius Pembrolizumab "Keytruda"
健康網訊：
Report Title: Market Report of Monoclonal Antibody Drugs in China (2022)
date: Sep, 2022
Format: Adobe PDF
Price: $ 9,900
￥ 61,800
Contact: Leo. (Mr. Lei Guangyu) / Ms. Xue zhe
Tel: 86-10-68012929-2103/2113
Mobile: 86-13810934380
E-mail: leigy@healthoo.com
Monoclonal Antibody(mAb) drugs is the largest category of products in the biopharmaceutical industry. This report makes detailed statistics
analysis on the scale growth rate of domestic market, sales volume price trends, competitions, etc. of mAb in various treatment fields and
different target categories in the past five years.
In recent years, the development marketing of monoclonal antibody drugs have increased rapidly. The number of monoclonal antibody drugs approved in China has increased from 13 in 2017 to 60 in 2022.
Graph 2 Number of mAB drugs listed in China from 2017 to July 2022
At present, monoclonal antibodies are mainly used in ten therapeutic fields, of which 33 are used for anti-tumor, 15 for rheumatoid other
autoimmune diseases, 3 for fundus maculopathy 2 for cholesterol lowering.
Table 4 Number of mAB drugs listed in China distribution of treatment fields from 2017 to July 2022
Monoclonal antibody drugs used in the field of anti-tumor therapy can be classified into four categories based on their mechanism of action market characteristics. One category is the traditional drugs targeting tumor related molecules, which can be classified into two sub
categories: inhibiting the key molecules of tumor survival, activating the innate adaptive immunity against tumors. The other three are the
most popular categories in recent years: immune checkpoint inhibitors, ADC (Antibody-drug conjugates) Bispecific antibody(BsAb) drugs.
Table 8 Number of mAB for anti-tumor in China from 2017 to July 2022
Brentuximab Vedotin for injection is a mAB against CD38. It is the world's first ADC drug developed by Seagen Takeda in 2011. Its brname is “Adcetris”. It is sold by Takeda outside North America.
In 2020, Brentuximab vedotin imported into China for the treatment of lymphoma, which is the most successful commercial ADC drug in the
field of blood tumor treatment. The specification is 50mg, the price decreased from 22,362 yuan/piece in 2020 to 16,860 yuan in 2021.
However, the negotiation of medical insurance has not been successful.
Graph 19 Sales volume price comparison of Brentuximab Vedotin for injection from 2020 to 2021
|
||||||||||||||||
